Allena Bets On Its Kidney Stone Treatment Despite Placebo Concerns
Execs are hoping having positive results in two studies will help raise funds for continued development. But high placebo results have caused concern for investors.
You may also be interested in...
VBI Is Ready To Take On HBV Vaccine Market
VBI’s Sci-B-Vac CONSTANT data firmly establishes the hepatitis B vaccine’s advantages over GSK’s longstanding Engerix-B, but it faces a tougher challenge with Heplisav-B from Dynavax.
Apellis Comes Closer To Taking On Alexion In PNH
Besting Alexion’s Soliris in a head-to-head Phase III trial portends a place in the market for Apellis’ competitor in paroxysmal nocturnal hemoglobinuria. But challenges dog both companies.
Iterum Anxiously Awaiting Other Results After SURE 3 Failure
Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.